5月23日早盘，港股医药生物板块强势领涨，恒生医疗保健指数截至发稿上涨1.69%，盘中一度涨逾 2.2%。 热门ETF中，恒生医疗指数ETF（159557）截至发稿上涨1.34%，成交额超1100万元，换手率超4%，交 投持续活跃。 成分股方面，绿叶制药涨超10%，海吉亚医疗、康哲药业涨超8%，亚盛医药-B、金斯瑞生物科技、信 达生物涨超5%。 消息面上，恒瑞医药拟在香港发行2.25亿股，今日挂牌交易，港股股价盘中一度涨超33%。 恒生医疗指数ETF（159557）标的指数为恒生医疗保健指数，该指数旨在反映恒生综合指数里主要经营 医疗保健业务成分股公司的表现。 广发证券表示，当前时刻建议重视港股创新药，原因如下： 3.政策及监管态度逐步转向对板块有利的情形。2023年下半年以来，政策层面出现了一系列积极信号， 标志着行业监管思路的调整，包括但不限于集采规则优化、创新药支持政策加码、医疗反腐常态化与纠 偏。 4.财务、估值及交易数据：营收增长、估值低位。财报层面：头部港股创新药公司受益于License-out放 量，营收和利润稳步增长。估值层面：医药板块相比于其他成长行业，估值处于相对安全的区间。 （本文机构观 ...

Luye Pharma Group Ltd. ( 於百慕達註冊成立之有限公司 ) 股份代號：2186 绿叶制药集团有限公司 年 報 2024 Luye Pharma Group Ltd. 绿叶制药集团有限公司 公司概覽 綠葉製藥集團有限公司（「本公司」，連同其附屬公司統稱為「本集團」）致力於在中華人民共和國（「中國」）、美利堅合眾國 （「美國」）、歐洲及其他國家或地區四個規模最大及增長迅速的治療領域（即腫瘤科、中樞神經系統（「中樞神經系統」）、心血 管系統及消化與代謝）進行創新藥品的開發、生產、推廣及銷售。本集團的產品組合包括超過30種產品，覆蓋包括大型製 藥市場中國、美國、歐洲及日本在內等全球80個以上國家及地區以及快速發展的新興市場。 在中國，本集團已經建立一個龐大的全國性銷售及分銷網絡，截至2024年12月31日止年度（「報告期」），其產品銷售往全國 31個省、自治區和直轄市。本集團透過約1,000名銷售和營銷人員及一個由約1,730家經銷商組成的網絡進行銷售、營銷及 分銷工作，共同令本集團將其產品銷往22,340多家醫院。於全球市場，本集團的業務覆蓋80個國家或地區，包括美國、歐 盟國家、日本、東南亞 ...

智通财经APP讯，绿叶制药(02186)发布公告，集团开发的罗替高汀贴片Rotigotine Luye已于近期在英国 上市，用于治疗早期和晚期特发性帕金森病的体征和症状，以及用于治疗中重度特发性不宁腿综合征。 该产品是首款在英国上市的Neupro®的仿制药，与Neupro®具有生物等效性。 Rotigotine Luye与Neupro®具有相同的剂量规格，在保持同等释药剂量的情况下，Rotigotine Luye具有更 低的载药量，贴片大小相较Neupro®小8%。此外，Rotigotine Luye的粘附基质层不含焦亚硫酸钠。焦亚 硫酸钠是一种已知可能引发过敏反应的接触性过敏原。 帕金森病是全球第二大常见的神经退行性疾病，患者人数超过1,000万人。该疾病会导致患者行动不便 以及心理健康、睡眠、疼痛和其他健康问题，其症状随时间的推移而恶化，严重影响患者的身心健康和 生活质量。不宁腿综合征则是一种常见的神经感觉障碍，影响全球约3%的人口。该疾病会导致患者出 现几乎不可抗拒的活动腿的欲望，症状严重时可显著干扰患者的日常活动。罗替高汀作为一种多巴胺受 体激动剂，可改善帕金森病患者的运动症状和非运动症状，并可有效缓 ...

智通财经APP讯，绿叶制药(02186)发布公告，集团自主研发的1类创新药若欣林®(盐酸托鲁地文拉法辛 缓释片)正式获得中国澳门药物监督管理局的上市批准，用于治疗抑郁症。 若欣林®是中国首个自主研发并拥有自主知识产权、用于治疗抑郁症的化药1类创新药。临床前研究显 示，若欣林®对于5-羟色胺(5-HT)、去甲肾上腺素(NE)和多巴胺(DA)均具有再摄取抑制作用;另有 PET/CT研究证实若欣林®可与大鼠和健康受试者脑内DA转运体结合，为其叁重再摄取抑制作用再添强 证。 若欣林®的3期临床研究结果证实其能够全面、稳定的治疗抑郁症，显著改善患者焦虑状态、阻滞╱疲 劳症状、快感缺失和认知能力，促进社会功能恢复，而且具有良好的安全性和耐受性，不引起嗜睡，不 影响性功能、体重和脂代谢。 一直以来，抑郁症伴随高复发率、高自杀率、高致残率，过往抗抑郁药虽然总体有效，但是存在明显未 满足的临床治疗需求。大多患者接受药物治疗后仍有残留症状，主要包括焦虑、认知损害、疲劳、快感 缺失等，严重损害社会功能，并显著加快抑郁症的再次复发。另外，亦易引发性功能障碍、体重增加、 情感迟钝、嗜睡等不良反应，影响患者的治疗依从性，也成为导致预后差 ...

智通财经APP讯，绿叶制药(02186)发布截至2024年12月31日止年度的年度业绩，收入60.61亿元(人民 币，下同)，同比减少1.33%;股东应占溢利4.72亿元，同比减少11.4%;每股基本盈利12.54分。 公告称，于中国市场，集团主要产品均于其四大主要治疗领域(肿瘤科、中枢神经系统、心血管及代谢) 具竞争地位。根据IQVIA数据显示，于报告期内，肿瘤科、代谢、中枢神经系统及心血管相关药品分别 构成中国第一、第二、第四及第五大药品市场。集团于中国的主要产品组合包括6款肿瘤治疗领域药品 (力扑素、博优诺、百拓维、赞必佳、希美纳及米美欣)、5款中枢神经系统治疗领域药品(思瑞康、若欣 林、瑞可妥、美比瑞及金悠平)、3款心血管治疗领域药品(血脂康、欧开及麦通纳)及1款代谢治疗领域药 品(贝希)。 就国际市场而言，集团的产品主要定位于中枢神经系统治疗领域，包括思瑞康、思瑞康缓释片、 Erzofri、Rykindo、利斯的明单日透皮贴剂、利斯的明多日透皮贴剂、芬太尼贴剂及丁丙诺啡贴剂。 于报告期内，集团中枢神经系统治疗领域产品销售额减少4.8%，达16.13亿元。肿瘤治疗领域产品销售 额减少1.8%，达20. ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 LUYE PHARMA GROUP LTD. 綠葉製藥集團有限公司 （於 百 慕 達 註 冊 成 立 之 有 限 公 司） （股 份 代 號：02186） – 2 – 綜合全面收益表 截 至2024年12月31日止年度之年度業績公告 財務摘要 – 1 – • 收入較截至2023年12月31日止年度減少人民幣81.7百萬元或1.3%至人民 幣6,061.4百 萬 元。 • EBITDA較截至2023年12月31日止年度增加人民幣114.2百萬元或5.5%至 人民幣2,191.7百 萬 元。 • 毛利較截至2023年12月31日止年度減少人民幣160.0百萬元或3.8%至人民 幣4,044.2百 萬 元，毛 利 率 達66.7%。 • 除稅前溢利較截至2023年12月31日止年度增加人民幣139.1百萬元或19.9% 至人民幣839.2百 萬 元。 • ...

Group 1 - The core point of the article is that Green Leaf Pharmaceutical has officially commenced the commercialization of its schizophrenia drug ERZOFRI® in the U.S. market [1] - The first batch of ERZOFRI®, valued at several tens of millions of U.S. dollars, has been shipped from the Green Leaf International Pharmaceutical Technology Industrial Park [1] - This marks a significant milestone for the company as it expands its presence in the U.S. pharmaceutical market [1]

Investment Rating - The report initiates coverage on Green Valley Pharmaceutical (2186 HK) with a "Buy" rating and a target price of HKD 2.90 [3][5] Core Views - Green Valley Pharmaceutical is a well-established pharmaceutical company with a broad sales network covering over 21,000 hospitals in China and 80 countries globally [1] - The company has a diversified product portfolio in oncology, cardiovascular, central nervous system (CNS), and digestive/metabolic fields, with several new drugs expected to be approved by 2025 [1] - The CNS business is expected to grow steadily, driven by strong demand for key products like Seroquel (思瑞康) and Rivastigmine Patch (利斯的明贴剂), with a projected 2023-26E CAGR of 13.2% [2] - The oncology business is expected to recover growth from 2025, supported by new products like Botuowei (百拓维) and Zanbiji (赞必佳) [2] - The cardiovascular business is expected to rebound in the second half of 2024, with a projected 2025-26E CAGR of 5.7% [2] - The digestive/metabolic business is expected to resume growth from 2025, driven by the potential approval of new drugs like Dulaglutide (度拉糖肽) and Aflibercept (阿柏西普) [2] Financial Performance - The company's revenue is expected to grow at a 2023-26E CAGR of 7.2%, with net profit projected to increase by 50.9% in 2024E, followed by 4.6% and 6.5% in 2025E and 2026E, respectively [5] - The oncology segment accounted for 31.0% of total revenue in H1 2024, followed by CNS (29.8%), cardiovascular (27.7%), and digestive/metabolic (7.1%) [17] Product Pipeline and Market Potential - **CNS Products**: Seroquel (思瑞康) is expected to maintain stable sales, while Rivastigmine Patch (利斯的明贴剂) and Ruoxinlin (若欣林) are expected to drive growth with 2023-26E CAGRs of 28.1% and 60.8%, respectively [2][28] - **Oncology Products**: Lipusu (力朴素) is expected to see a moderate recovery in sales from H2 2024, while Botuowei (百拓维) and Zanbiji (赞必佳) are expected to contribute significantly to growth from 2025 [2][44][48] - **Cardiovascular Products**: Xuezhikang (血脂康) is expected to recover sales in H2 2024, while Oukai (欧开) is projected to grow at a 2023-26E CAGR of 23.2% [56][57] - **Digestive/Metabolic Products**: The segment is expected to resume growth from 2025, driven by the potential approval of Dulaglutide (度拉糖肽) and Aflibercept (阿柏西普) [2][60] Valuation and Market Position - The company is currently undervalued compared to industry peers, with a target price of HKD 2.90 based on a 12.0x 2025E PER [5] - Green Valley Pharmaceutical has a strong market position in China, with a broad product portfolio and extensive sales network [1][17]

Financial Performance - Revenue increased by RMB 170.5 million or 5.9% to RMB 3,074.6 million for the six months ended June 30, 2024[8]. - Gross profit rose by RMB 135.2 million or 7.0% to RMB 2,078.6 million, with a gross margin of 67.6%[8]. - Net profit attributable to shareholders increased by RMB 237.8 million or 158.5% to RMB 387.8 million[8]. - EBITDA grew by RMB 288.9 million or 33.3% to RMB 1,156.1 million[8]. - The company recorded a revenue increase of 5.9% to RMB 3,074.6 million for the six months ending June 30, 2024[11]. - The company's net profit for the six months ended June 30, 2024, was approximately RMB 438.2 million, an increase of about RMB 292.8 million or 201.4% compared to RMB 145.4 million in the same period last year[60]. - The total comprehensive income for the period was RMB 440,312,000, compared to RMB 219,383,000 in 2023, which is an increase of approximately 100%[106]. - Basic earnings per share for the period was RMB 10.31, compared to RMB 4.06 in the previous year, marking an increase of 153%[103]. Research and Development - The company has 27 products under development in China, including 18 oncology products[4]. - The R&D team consists of 720 employees, including 66 PhDs and 351 Master's degree holders[3]. - The company has expanded its R&D capabilities to include four chemical drug platforms and is supported by advanced biotechnological platforms[28]. - The company aims to balance clinical development risks by strategically allocating resources to develop validated compounds and new drugs[28]. - The company plans to continue optimizing its product pipeline and increase investment in new molecular innovative drugs, with several biopharmaceuticals expected to be launched in China and overseas by 2025[48]. Product Development and Pipeline - The group has over 30 domestic and more than 10 international products in the pipeline, focusing on innovative drug delivery technologies[11]. - The group is actively developing strategic initiatives in cell therapy and gene therapy[11]. - The company has received approval for four new oncology products in mainland China and one in Hong Kong and Macau, enhancing its product portfolio[44]. - The company has ongoing research and development for multiple products, with a total allocation of HKD 276.55 million for clinical trials and related management[77]. Market Performance - Revenue from the oncology treatment segment increased by 25.3% to RMB 1,140.9 million, while revenue from the central nervous system treatment segment rose by 20.9% to RMB 822.7 million[12]. - Revenue from the cardiovascular treatment segment decreased by 21.9% to RMB 763.3 million, and revenue from the metabolic treatment segment fell by 20.8% to RMB 195.7 million[12]. - The oncology treatment sector has the potential to generate over RMB 1 billion in annual revenue increment from five new product launches in the short term, with long-term market potential exceeding RMB 5 billion[44]. - The CNS treatment sector is projected to have a long-term market potential exceeding RMB 5 billion, driven by new products like 若欣林 and Erzofri[46]. Sales and Distribution - The company has established a national sales and distribution network covering over 21,450 hospitals in China[3]. - The company has over 50 global sales partnerships, enhancing its market presence across 80 countries and regions[38]. - The company aims to leverage its extensive hospital coverage to enhance brand recognition and expand market reach[39]. - The company’s sales and marketing model is supported by approximately 1,000 sales personnel and a network of about 1,650 distributors[39]. Financial Position and Assets - The total assets increased to RMB 27,198.5 million as of June 30, 2024[9]. - As of June 30, 2024, the company had net current assets of approximately RMB 2,761.4 million, with a current ratio slightly decreasing from 1.32 to 1.28 due to a slight increase in borrowings[61]. - As of June 30, 2024, the total interest-bearing loans and borrowings of the group amounted to approximately RMB 8,479.2 million, an increase from RMB 7,486.1 million as of December 31, 2023[62]. - The group's debt-to-equity ratio increased from 55.3% as of December 31, 2023, to 60.2% as of June 30, 2024, primarily due to the increase in total borrowings during the reporting period[63]. Corporate Governance and Compliance - The company has adhered to high standards of corporate governance, with the exception of a deviation regarding the separation of the roles of Chairman and CEO[82]. - The audit committee reviewed the unaudited interim financial statements for the six months ending June 30, 2024, and recommended their adoption to the board[85]. - Major shareholders include Green Leaf Pharmaceutical Investment Limited, holding 1,259,196,703 shares (33.47%), and Hillhouse Capital Management, holding 552,324,108 shares (14.68%)[89]. Shareholder Information - Liu Dianbo holds 1,259,196,703 shares (33.47%) and 192,317,950 short positions (5.11%) in the company[90]. - Nelumbo Investments Limited owns 70% of the issued share capital of Green Leaf Life Sciences Group Limited, which is fully owned by Liu Dianbo's family trust[91]. - The total number of shares granted under the share incentive plan as of December 31, 2023, is 55,355,000[96]. Cash Flow and Liquidity - Operating cash flow for the six months ended June 30, 2024, was a net outflow of RMB 394,400,000, a significant decrease from a net inflow of RMB 689,727,000 in the same period of 2023[118]. - The company reported a net cash outflow from investing activities of RMB 505,313,000 for the six months ended June 30, 2024, compared to RMB 78,019,000 in the same period of 2023[118]. - The company’s cash flow from financing activities for the six months ended June 30, 2024, was a net inflow of RMB 980,399,000, down from RMB 1,522,952,000 in the same period of 2023[118]. Investment and Financing Activities - An agreement was signed on July 22, 2024, for an investment of up to RMB 1,600 million in the group's subsidiary, with the investor acquiring a 34.8% stake in Shenzhen Green Leaf[68]. - The company issued USD 180 million convertible bonds at a 6.25% interest rate, with net proceeds of approximately HKD 1,382.76 million, aimed at improving liquidity and settling short-term debts[76]. - The company has secured bank loans totaling RMB 8,479,198,000, with interest rates ranging from 2.65% to 6.25% and maturity dates extending to 2031[164][169]. Risk Management - The company identified potential risks related to Pillar Two income tax regulations, although these regulations have not yet been enacted in mainland China or Hong Kong[137]. - The company has not adopted any supplier financing arrangements, which indicates a stable financial structure without reliance on external financing[123].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown significant profit growth driven by both new and existing products, with a notable increase in revenue and net profit [1] - The company reported a revenue of HKD 30.75 billion, a year-on-year increase of 5.87%, and a net profit of HKD 3.88 billion, up 158.59% year-on-year [1] - The report highlights a substantial decrease in expenses, leading to a rapid recovery in profits, with a total expense ratio of 56.98%, down 13.38 percentage points year-on-year [1] - The oncology segment generated revenue of HKD 11.41 billion, a year-on-year increase of 25.3%, while the central nervous system segment saw revenue of HKD 8.23 billion, up 20.9% [1] - The company has received approvals for five products in China and the U.S. during the reporting period, enhancing its product portfolio [1] Financial Performance Summary - Revenue projections for 2024-2026 are estimated at HKD 68.12 billion, HKD 83.98 billion, and HKD 99.23 billion, with year-on-year growth rates of 11%, 23%, and 18% respectively [2] - Net profit forecasts for the same period are HKD 7.76 billion, HKD 12.41 billion, and HKD 15.94 billion, with growth rates of 46%, 60%, and 28% respectively [2] - The company’s gross margin is expected to improve from 68.44% in 2023 to 71.50% in 2024, reaching 73.79% in 2025 [3] - Return on equity (ROE) is projected to increase from 4.25% in 2023 to 10.14% by 2026 [3] Product Development and Market Position - The company is focusing on expanding its product matrix, with new products like Erzofri and 金悠平 receiving market approvals [1] - The report indicates that the company is well-positioned for growth in the central nervous system and oncology markets, with a clear path for future revenue generation [1][2]